Literature DB >> 20067290

Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor.

Ciaran G Carolan1, Gerald P Dillon, Denise Khan, Sheila A Ryder, Joanne M Gaynor, Sean Reidy, Juan F Marquez, Mike Jones, Valerie Holland, John F Gilmer.   

Abstract

Isosorbide-2-benzyl carbamate-5-benzoate is a highly potent and selective BuChE inhibitor. Meanwhile, isosorbide-2-aspirinate-5-salicylate is a highly effective aspirin prodrug that relies on the salicylate portion to interact productively with human BuChE. By integrating the salicylate group into the carbamate design, we have produced isosorbide-2-benzyl carbamate-5-salicylate, an inhibitor of high potency (150 pM) and selectivity for human BuChE over AChE (666000) and CES2 (23000). Modeling and mutant studies indicate that it achieves its exceptional potency because of an interaction with the polar D70/Y332 cluster in the PAS of BuChE in addition to pseudosubstrate interactions with the active site.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20067290     DOI: 10.1021/jm9014845

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Design, synthesis, in vivo and in vitro studies of 1,2,3,4-tetrahydro-9H-carbazole derivatives, highly selective and potent butyrylcholinesterase inhibitors.

Authors:  Roshanak Ghobadian; Roghaieh Esfandyari; Hamid Nadri; Alireza Moradi; Mohammad Mahdavi; Tahmineh Akbarzadeh; Hossein Khaleghzadeh-Ahangar; Najmeh Edraki; Mohammad Sharifzadeh; Mohsen Amini
Journal:  Mol Divers       Date:  2019-03-29       Impact factor: 2.943

2.  Neuroprotective Tri- and Tetracyclic BChE Inhibitors Releasing Reversible Inhibitors upon Carbamate Transfer.

Authors:  Fouad H Darras; Beata Kling; Jörg Heilmann; Michael Decker
Journal:  ACS Med Chem Lett       Date:  2012-08-22       Impact factor: 4.345

Review 3.  Inhibitory potential of nitrogen, oxygen and sulfur containing heterocyclic scaffolds against acetylcholinesterase and butyrylcholinesterase.

Authors:  Rami J Obaid; Nafeesa Naeem; Ehsan Ullah Mughal; Munirah M Al-Rooqi; Amina Sadiq; Rabab S Jassas; Ziad Moussa; Saleh A Ahmed
Journal:  RSC Adv       Date:  2022-07-12       Impact factor: 4.036

4.  Evaluating Fmoc-amino acids as selective inhibitors of butyrylcholinesterase.

Authors:  Jeannette Gonzalez; Jennifer Ramirez; Jason P Schwans
Journal:  Amino Acids       Date:  2016-08-13       Impact factor: 3.520

5.  Synthesis and biological evaluation of 8-hydroxy-2,7-naphthyridin-2-ium salts as novel inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).

Authors:  M Schiedel; A Fallarero; C Luise; W Sippl; P Vuorela; M Jung
Journal:  Medchemcomm       Date:  2017-01-13       Impact factor: 3.597

6.  Development of an in-vivo active reversible butyrylcholinesterase inhibitor.

Authors:  Urban Košak; Boris Brus; Damijan Knez; Roman Šink; Simon Žakelj; Jurij Trontelj; Anja Pišlar; Jasna Šlenc; Martina Gobec; Marko Živin; Larisa Tratnjek; Martina Perše; Kinga Sałat; Adrian Podkowa; Barbara Filipek; Florian Nachon; Xavier Brazzolotto; Anna Więckowska; Barbara Malawska; Jure Stojan; Irena Mlinarič Raščan; Janko Kos; Nicolas Coquelle; Jacques-Philippe Colletier; Stanislav Gobec
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

7.  Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.

Authors:  Weiam Hussein; Begüm Nurpelin Sağlık; Serkan Levent; Büşra Korkut; Sinem Ilgın; Yusuf Özkay; Zafer Asım Kaplancıklı
Journal:  Molecules       Date:  2018-08-14       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.